MyProstateScore 2.0 (MPS2) is now available for at-home sample collection.
Home

Predict Prostate Cancer Risk with Leading Accuracy

MyProstateScore 2.0 (MPS2) offers physicians and patients the most comprehensive and flexible prostate cancer risk assessment tool.

Predict Prostate Cancer Risk with Leading Accuracy

MyProstateScore 2.0 (MPS2) offers physicians and patients the most comprehensive and flexible prostate cancer risk assessment tool.

Doctor and Patient - MyProstateScore 2.0

MYPROSTATESCORE 2.0

Clear Results. Confident Decision.

MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing a comprehensive array of 18 unique gene transcripts. Our algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility, allowing MPS2 to be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference. Receive individualized reports with results tailored to unique patient and clinical context.

Urine Sample icon

Urine Sample

Magnifying Glass icon

18 Biomarkers

Needle icon

Optional Clinical Factors

Report icon

Individualized Reports

Why Lynx Dx?

Lynx Dx provides superior diagnostic testing services to help people live healthy and productive lives.

[wpcode id=”521″]

Stay Up To Date

Resources

Industry news, men’s health information, and expert prostate cancer and risk assessment research.